Edition:
United Kingdom

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

107.80EUR
17 Jun 2019
Change (% chg)

€-0.80 (-0.74%)
Prev Close
€108.60
Open
€108.30
Day's High
€108.70
Day's Low
€106.20
Volume
322,034
Avg. Vol
409,723
52-wk High
€111.80
52-wk Low
€70.64

About

Galapagos NV is a Belgium-based clinical-stage biotechnology company. The Company is focused on the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and... (more)

Overall

Beta: 1.44
Market Cap(Mil.): €5,931.17
Shares Outstanding(Mil.): 54.61
Dividend: --
Yield (%): --

Financials

  GLPG.AS Industry Sector
P/E (TTM): -- 103.12 37.45
EPS (TTM): -0.71 -- --
ROI: -3.68 7.69 12.16
ROE: -3.92 8.19 16.93

BRIEF-Galapagos, MorphoSys Announce Initiation Of Gecko Phase 2 Study

* GECKO IS A PHASE 2 STUDY TESTING A SUBCUTANEOUS FORMULATION OF MOR106 IN COMBINATION WITH TOPICAL CORTICOSTEROIDS IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS

24 Apr 2019

Shares in Galapagos jump 15 percent after arthritis drug results

AMSTERDAM Shares in Belgian drugmaker Galapagos surged nearly 16 percent on Friday after the company said it had seen positive results from several safety and efficacy trials of its rheumatoid arthritis drug filgotinib.

29 Mar 2019

Shares in Galapagos jump 15 pct after arthritis drug results

AMSTERDAM, March 29 Shares in Belgian drugmaker Galapagos surged nearly 16 percent on Friday after the company said it had seen positive results from several safety and efficacy trials of its rheumatoid arthritis drug filgotinib.

29 Mar 2019

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE THROUGH WARRANT EXERCISES

21 Mar 2019

BRIEF-Galapagos FY Revenue Up At 317.8 Million Euros

* SAID ON THURSDAY FY REVENUE EUR 317.8 MLN VS EUR 155.9 MLN YR AGO

22 Feb 2019

BRIEF-Galapagos And Fibrocor Sign Partnership Focusing On Fibrosis

* SAID ON FRIDAY FIBROCOR THERAPEUTICS L.P. AND GALAPAGOS SIGN PARTNERSHIP FOCUSING ON FIBROSIS

07 Jan 2019

Earnings vs. Estimates